EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

FGFR Alterations in Thyroid Carcinoma: A Novel Class of Primary Drivers with Significant Therapeutic Implications and Secondary Molecular Events Potentially Mediating Resistance in Thyroid Malignancy

Mark F Sabbagh iD, Tyler Janovitz, Dora Dias-Santagata, Stephanie Siegmund, Valentina Nardi, Lori J Wirth iD, Gregory W Randolph, Jochen K Lennerz, Brennan Decker, Vania Nose, Bayan A Alzumaili iD, William C Faquin iD und 5 weitere

Thyroid® · 2024

DOI: 10.1089/thy.2024.0216 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Thyroid®, 2024. Verfasst von Mark F Sabbagh und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: Thyroid Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diagnostic classification of thyroid malignancy is primarily accomplished through examination of histomorphological features and may be substantiated and clarified by molecular data. Individual molecular drivers show relatively robust and specific associations with histological subtypes of thyroid malignancy, including BRAF sequence variants and kinase gene fusions in papillary thyroid carcinoma, predominantly RAS variants in follicular-patterned neoplasia, and additional “late” mutations affecting TERT promoter, TP53 , and the PI3K/AKT/PTEN pathway in high-grade malignancies. Given the oncogenic role of FGFR , particularly FGFR1-3 , the goal of this study was to explore the role of FGFR in thyroid carcinoma biology.

Methods

We completed a multicenter retrospective observational study for thyroid carcinomas with pathogenic alterations in the FGFR gene family. We performed this study by querying the molecular data accumulated for thyroid carcinomas from each center.

Results

Overall, 5030 sequenced thyroid malignancies were reviewed, yielding 17 tumors with FGFR alterations, including 11 where FGFR was the primary molecular driver and 6 where FGFR was a secondary pathogenic alteration, with a subset for which there was available clinical follow-up data. Of the 11 carcinomas with an FGFR driver, 9 were gene fusions involving FGFR2:VCL (4 tumors), TG::FGFR1 (3 tumors), FGFR2::CIT , and FGFR2::SHTN1 , and the remaining 2 were driven by FGFR1 amplification. In the 6 tumors where a canonical driver of thyroid neoplasia was present (5 cases) or no clear primary driver was detected (1 case), sequencing detected secondary FGFR2 p.W290C, p.Y375C, and p.N549K, as well as FGFR1 p.N546K in the respective tyrosine kinase domains, some at subclonal variant allele frequencies.

Conclusions

This study presents the first description of a collection of thyroid carcinomas grouped by primary driver alterations in FGFR , as well as a cohort of thyroid tumors with secondary alterations that potentially lead to tumor progression or resistance to targeted therapy. Given the availability of small molecular inhibitors targeting oncogenic FGFR , this study emphasizes the significant implications for patients from identification of FGFR alterations as they are currently under-recognized in the literature and, most importantly, have potential novel treatment options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsHumansRetrospective StudiesMaleMutationFemaleMiddle AgedReceptor, Fibroblast Growth Factor, Type 1Drug Resistance, NeoplasmReceptors, Fibroblast Growth FactorAdultAgedReceptor, Fibroblast Growth Factor, Type 2Thyroid Cancer, Papillary

Stichwörter der Autor:innen

FGFRdrug resistancenext-generation sequencingtargeted therapythyroid cancerthyroid carcinoma

Substanzen

Receptor, Fibroblast Growth Factor, Type 1Receptors, Fibroblast Growth FactorReceptor, Fibroblast Growth Factor, Type 2FGFR1 protein, human

Autor:innen und Institutionen

  • Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Foundation Medicine, Inc., Cambridge, Massachusetts, USA.
  • Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
  • Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Departments of Otolaryngology - Head and Neck Surgery, Massachusetts Eye and Ear and Harvard Medical School, Boston, MA, USA.
  • BostonGene Corporation, Waltham, Massachusetts, USA.

ORCID-Profile: Mark F Sabbagh, Lori J Wirth, Bayan A Alzumaili, William C Faquin, Peter M Sadow, Adam S Fisch

Zitieren

APA

Sabbagh, M. F., Janovitz, T., Dias-Santagata, D., Siegmund, S., Nardi, V., Wirth, L. J., Randolph, G. W., Lennerz, J. K., Decker, B., Nose, V., Alzumaili, B. A., Faquin, W. C., Barletta, J. A., Le, L. P., Iafrate, A. J., Sadow, P. M., & Fisch, A. S. (2024). FGFR Alterations in Thyroid Carcinoma: A Novel Class of Primary Drivers with Significant Therapeutic Implications and Secondary Molecular Events Potentially Mediating Resistance in Thyroid Malignancy. Thyroid®. https://doi.org/10.1089/thy.2024.0216

Vancouver

Sabbagh MF, Janovitz T, Dias-Santagata D, Siegmund S, Nardi V, Wirth LJ, et al. FGFR Alterations in Thyroid Carcinoma: A Novel Class of Primary Drivers with Significant Therapeutic Implications and Secondary Molecular Events Potentially Mediating Resistance in Thyroid Malignancy. Thyroid®. 2024. doi:10.1089/thy.2024.0216

BibTeX
@article{Sabbagh2024,
  author = {Sabbagh, Mark F and Janovitz, Tyler and Dias-Santagata, Dora and Siegmund, Stephanie and Nardi, Valentina and Wirth, Lori J and Randolph, Gregory W and Lennerz, Jochen K and Decker, Brennan and Nose, Vania and Alzumaili, Bayan A and Faquin, William C and Barletta, Justine A and Le, Long P and Iafrate, A John and Sadow, Peter M and Fisch, Adam S},
  title = {FGFR Alterations in Thyroid Carcinoma: A Novel Class of Primary Drivers with Significant Therapeutic Implications and Secondary Molecular Events Potentially Mediating Resistance in Thyroid Malignancy},
  journal = {Thyroid®},
  year = {2024},
  doi = {10.1089/thy.2024.0216}
}
Kostenlos starten →